i-Butoxyradikal | 26397-34-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: i-Butoxyradikal
• 英文别名: isobutyloxyl；Isobutoxyl
• CAS: 26397-34-2
• 化学式: C₄H₉O
• 分子量: 73.1149
• InChiKey: PBRXKNKPUMMYPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  5
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  1
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  i-Butoxyradikal 在 H₂⁽¹⁵⁾NO 作用下， 生成 亚硝酸异丁酯 、 异丁醛
  参考文献：
  名称：

  歧化烷氧基与一氧化氮的比例

  摘要：

  DOI：

  10.1021/j100259a041
• 作为产物：
  描述：

  亚硝酸异丁酯 生成 i-Butoxyradikal
  参考文献：
  名称：

  歧化烷氧基与一氧化氮的比例

  摘要：

  DOI：

  10.1021/j100259a041

文献信息

• Laser flash photolysis determination of absolute rate constants for reactions of bromine atoms in solution
  作者：J. C. Scaiano、M. Barra、M. Krzywinski、R. Sinta、G. Calabrese

  DOI：10.1021/ja00071a048

  日期：1993.9

  dibromides at 266 nm produces bromine atoms with a quantum yield of ∼2.0. This results from an efficient primary photocleavage of a C-Br bond, followed by rapid elimination of a second bromine atom from radicalsofthe type RCH-CH 2 Br. This cleavage occurs with a lifetime of <20 ns at room temperature. Bromine atoms react with bromine ions with a rate constant of 1.6×10 10 M -1 s -1 to yield Br 2 .-

  邻位二溴化物在 266 nm 处的光分解产生量子产率为~2.0 的溴原子。这是由于 C-Br 键的有效初级光裂解，然后从 RCH-CH 2 Br 型自由基中快速消除了第二个溴原子。这种裂解在室温下以 <20 ns 的寿命发生。溴原子与溴离子以1.6×10 10 M -1 s -1 的速率常数反应生成Br 2 .- ，一种易于检测且寿命长的自由基离子。该反应可用作探针以确定溴原子其他反应的绝对速率常数
• Effects of oral and transdermal 17β-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women
  作者：Christopher P. Spencer、Ian F. Godsland、Alison J. Cooper、David Ross、Malcolm I. Whitehead、John C. Stevenson

  DOI：10.1053/meta.2000.6238

  日期：2000.6

  Few studies have examined the effects of 17 beta-estradiol on parameters of insulin and glucose metabolism. We studied 42 healthy, untreated postmenopausal women seeking relief from menopausal symptoms. They were randomized to receive either oral 17 beta-estradiol 2 mg daily combined with sequential oral norethindrone acetate (NETA) 1 mg daily from days 12 to 22, or transdermal 17 beta-estradiol 0.05 mg daily combined with sequential oral NETA 1 mg daily from days 17 to 28. Intravenous glucose tolerance tests (IVGTTs) were performed at baseline and after 48 weeks (estrogen-alone phase) and 48 weeks (combined phase) of completed therapy. Mathematical modeling analysis of plasma glucose, insulin, and C-peptide concentration profiles provided measures of insulin resistance, secretion, and elimination. Both types of therapy were associated with a decrease in fasting insulin and glucose levels. Insulin sensitivity was increased by oral estradiol during the estrogen-alone phase but was reversed by the addition of NETA. Transdermal estradiol did not affect insulin sensitivity. Hepatic insulin uptake and insulin secretion were increased with both types of treatment. The oral regimen of estradiol therapy was favorable to both insulin elimination and sensitivity. Transdermal estradiol therapy had relatively few effects on insulin metabolism. Copyright (C) 2000 by W.B. Saunders Company.
• Rehorek, Detlef, Zeitschrift fur Chemie, 1980, vol. 20, # 8, p. 312 - 313
  作者：Rehorek, Detlef

  DOI：——

  日期：——